About mouth ulcers
Mouth ulcers are sores that form in the mucous membranes of the oral cavity. They are noncritical and do not pose a health hazard. Mouth ulcers can be caused by oral injury or may arise as a result of underlying disease. They can be associated with intense or moderate pain. The etiology of mouth ulcers include stress, injury, infection, allergy, genetic tendency, and nutritional deficiencies. Treatment involves identification of the cause. The ulcers normally heal by themselves in 10-14 days. Medical treatment is required if the condition persists. Various treatment options, such as antimicrobials, anesthetics, corticosteroids, analgesics, and antihistamines are used to treat them.
Technavio's analysts forecast the global mouth ulcer treatment market to grow at a CAGR of 4.18% over the period 2014-2019.
Covered in this report
The report covers the present scenario and growth prospects of the global mouth ulcer treatment market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various pharmaceutical products used in the treatment of mouth ulcers.
Technavio's report, Global Mouth Ulcer Treatment Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global mouth ulcer treatment market and its growth prospects in the coming years. The report includes a discussion on the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Mouth Ulcer Treatment Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Mouth Ulcer Treatment Market: 3M Healthcare, Blistex, Church & Dwight, Taro Pharmaceuticals and Valeant Pharmaceuticals
Other Prominent Vendors in the market are: Blairex Laboratories, Bristol-Myers Squibb, Diomed, Dr.Reddy's, EPIEN Medical, Focus Pharmaceuticals, GlaxoSmithKline, Henry Schein, Macoven Pharmaceuticals, Meda pharmaceuticals, Novartis, Pfizer, Sinclair IS Pharma, Svizera Labs, the Colgate-Palmolive Company and Zila Pharmaceuticals
Commenting on the report, an analyst from Technavio’s team said: “A single medication that relieves all mouth ulcer associated conditions does not yet exist. Hence, the use of multiple classes of drugs for treatment is in use, including pain relievers such as Anbesol, Num-Zit, and Zilactin-B; antisepsis drugs such as Peridex, and Orajel; and anti-inflammatory drugs such as Aphthasol and Orabase-HCA. This results in market fragmentation, affecting market growth.”
According to the report, the prevalence of mouth ulcers is increasing, with 15-30% of the global population now affected by them. The factors contributing to this increase include trauma, stress, foods, hormonal imbalances, and tobacco smoking. Mouth disorders are also common among the aging population. According to the WHO, approximately 2 billion people will be aged 60 years or older by 2050. As the prevalence of mouth ulcers increases, the number of people seeking treatment will also rise, thereby leading to the growth of the market.
Further, the report states that individuals are less inclined towards using drugs to treat mouth ulcers, which negatively affects the growth of the market.
3M Healthcare, Blistex, Church & Dwight, Taro Pharmaceuticals,Valeant Pharmaceuticals, Blairex Laboratories, Bristol-Myers Squibb, Diomed, Dr.Reddy's, EPIEN Medical, Focus Pharmaceuticals, GlaxoSmithKline, Henry Schein, Macoven Pharmaceuticals, Meda pharmaceuticals, Novartis, Pfizer, Sinclair IS Pharma, Svizera Labs, the Colgate-Palmolive Company, Zila Pharmaceuticals